ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos60.8 M52.4 M43.7 M38.9 M51.1 M186.1 MInvestigación y desarrollo9.1 M15.1 M12.5 M13.5 M12.1 M53.2 MBeneficio operativo-9.5 M49.9 M1.6 M76.5 M-27.9 M100.1 MTotal de ingresos no operativos-18.1 M42.8 M-18.4 M-18.9 M-22.8 M-17.3 MGastos por intereses, netos de intereses capitalizados14.8 M14.7 M14.7 M15.2 M14.7 M59.3 MIngresos no operativos, una vez deducidos los gastos por intereses-29.6 M-41.6 M-29.4 M-30.4 M-29.4 M-130.8 MIngresos/gastos extraordinarios-3.3 M69.7 M-3.7 M-3.7 M-8.1 M54.2 MBeneficio antes de impuestos-27.6 M92.7 M-16.8 M57.6 M-50.7 M82.8 MParticipación en los beneficios——————Impuestos3.7 M24.7 M-4.8 M6.4 M3.9 M30.2 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos-2.6 M11.3 M-2.2 M-400 K-9.1 M-400 KBeneficio neto antes de actividades interrumpidas-31.3 M68 M-12 M51.2 M-54.6 M52.6 MOperaciones suspendidas——————Beneficio neto-31.3 M68 M-12 M51.2 M-54.6 M52.6 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-31.3 M68 M-12 M51.2 M-54.6 M52.6 MBeneficio básico por acción-0.551.25-0.220.96-1.010.98Beneficio por acción diluido-0.451.19-0.220.91-0.950.93Número medio de acciones ordinarias53 M54.4 M54.2 M53.2 M53.5 M215.3 MAcciones diluidas53 M57.3 M54.2 M56.5 M56.7 M224.7 MEBITDA-44.5 M-65.3 M-84.5 M-22.7 M-139.4 M-311.9 MEBIT-70.1 M-91.3 M-110 M-50.5 M-164.9 M-416.7 MCosto de los ingresos—88.5 M66.9 M85.9 M84.9 M326.2 MOtros costes de producción——————Amortización y depreciación (flujo de caja)26 M25.4 M23.5 M23.4 M23.5 M95.8 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.